A Feasibility Study to Determine if a Novel Patient-derived Explant Platform Can Produce Drug Sensitivity Scores Within a Clinically Relevant Time Frame in Patients With CNS Tumors

What this Trial Is About

Researchers are evaluating a new method to study drug responses using tumor tissue taken from patients with central nervous system (CNS) tumors, including both children and adults. This study explores the feasibility of a novel patient-derived explant (PDE) platform, which uses small pieces of tumor tissue maintained outside the body to predict how tumors might respond to different drugs. Since CNS tumors vary greatly, this approach aims to provide a better tool to identify the most effective treatments for each patient. Participants will have tumor tissue collected during their planned surgical removal of CNS tumors. The collected tissue will be used to create PDEs that preserve important aspects of the tumor's characteristics. Researchers will then generate drug sensitivity scores from these PDEs to assess how well different drugs might work. The study also aims to measure how successfully these PDEs can be scaled up based on the size of the tumor sample. During the study, participants will undergo biospecimen collection at surgery. Researchers will analyze the tissue samples within 28 days to determine the proportion of specimens that yield drug response scores and assess the scalability of the specimens. The study involves no additional treatments or interventions beyond the planned surgery. Participation duration and safety monitoring details are based on the observational nature of the study and the analysis timeline.

Brain Slice Explants to Predict Drug Response in Brain Tumors